JP2000302672A - Chewable coated tablet - Google Patents

Chewable coated tablet

Info

Publication number
JP2000302672A
JP2000302672A JP11109212A JP10921299A JP2000302672A JP 2000302672 A JP2000302672 A JP 2000302672A JP 11109212 A JP11109212 A JP 11109212A JP 10921299 A JP10921299 A JP 10921299A JP 2000302672 A JP2000302672 A JP 2000302672A
Authority
JP
Japan
Prior art keywords
tablet
chewable
coated
diameter
hardness
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP11109212A
Other languages
Japanese (ja)
Inventor
Kengo Tateshimo
謙吾 舘下
Yoshihiro Tsukuda
義洋 佃
Yasuo Nakagawa
泰緒 中川
Takashi Yamazaki
孝 山崎
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Taisho Pharmaceutical Co Ltd
Original Assignee
Taisho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co Ltd filed Critical Taisho Pharmaceutical Co Ltd
Priority to JP11109212A priority Critical patent/JP2000302672A/en
Publication of JP2000302672A publication Critical patent/JP2000302672A/en
Pending legal-status Critical Current

Links

Landscapes

  • Medicinal Preparation (AREA)

Abstract

PROBLEM TO BE SOLVED: To obtain a coated tablet chewable as a chewable tablet, and hardly causing problems such as breakage by selecting the hardness of an inner core tablet of the coated tablet so as to be within a given range regulated by the diameter of the inner core tablet. SOLUTION: This chewable coated tablet comprises an inner core tablet (preferably the one containing easily oxidizable medicine or a discoloring medicine as an active ingredient), and a coating layer for coating the inner core tablet (preferably sugar coating), and obtained by regulating the hardness (N) of the inner core tablet so as to be 4-8 times as much as the value of the diameter (mm) of the tablet. The shape of the tablet can be formed into the disk shape same as a conventional chewable tablet. The diameter of the inner core tablet of the tablet is preferably 5-14 mm, and the thickness is preferably >=0.3, especially 0.5-0.75 when the diameter of the tablet is 1. As a result, a variety of medicines in a shape of the chewable tablet can be provided.

Description

【発明の詳細な説明】DETAILED DESCRIPTION OF THE INVENTION

【0001】[0001]

【発明の属する技術分野】本発明は咀嚼可能な錠剤に関
し、特に糖衣のような被覆層を有していながら十分に咀
嚼可能な錠剤に関する。
BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a chewable tablet, and more particularly to a tablet which can be sufficiently chewed while having a coating layer such as sugar coating.

【0002】[0002]

【従来の技術】咀嚼可能な錠剤、いわゆるチュアブル錠
は口腔内で溶解あるいは咀嚼して服用するための薬剤等
の経口投与用の形態の一つであり、できるだけ小径の剤
形で服用された方が好ましい医薬活性成分等について、
服用前には錠剤としての取り扱いやすさを有しながら、
前記のような望ましい服用形態を満足できる投与形態の
一つとして汎用されている。
2. Description of the Related Art Chewable tablets, so-called chewable tablets, are one of the forms for oral administration of drugs or the like for dissolving or chewing in the oral cavity and taking them in a form as small as possible. For preferred pharmaceutically active ingredients,
Before taking, while being easy to handle as a tablet,
It is widely used as one of the administration forms that can satisfy the desirable dosage form as described above.

【0003】従来のチュアブル錠は、口腔内で噛み砕か
れるものであることから、錠剤全体に甘味料、香味剤等
の成分を加えて咀嚼しやすくしたものであり、その点か
ら糖衣のような被覆は設けられていなかった。
[0003] Conventional chewable tablets are chewable in the oral cavity, and are thus made easy to chew by adding components such as sweeteners and flavoring agents to the whole tablet. No coating was provided.

【0004】しかし、酸素や水分の存在により酸化、変
色等の変化を起こしやすい薬剤があり、そのような薬物
を上記のような従来の被覆のないチュアブル錠に含有さ
せる場合、抗酸化剤や乾燥剤等をチュアブル錠容器に共
存させなければならず、あるいは包装形態によってはそ
のような薬物をチュアブル錠に含有させることができな
い場合があった。
[0004] However, there are drugs which are liable to undergo changes such as oxidation and discoloration due to the presence of oxygen and moisture. When such drugs are contained in the conventional uncoated chewable tablets as described above, antioxidants and drying agents are required. An agent or the like must coexist in a chewable tablet container, or such a drug cannot be contained in a chewable tablet in some cases depending on the form of packaging.

【0005】そこでチュアブル錠に糖衣のような酸素、
水分を遮断する被覆層を設けることが考えられるが、従
来の被覆のないものとして選択された硬度を有するチュ
アブル錠に糖衣等の被覆を施すと、チュアブル錠として
咀嚼がしにくいものとなってしまうことが判明した。
[0005] Therefore, chewable tablets are coated with oxygen such as sugar coating,
It is conceivable to provide a coating layer that blocks moisture, but when a chewable tablet having a hardness selected as a conventional uncoated one is coated with sugar coating or the like, it becomes difficult to chew as a chewable tablet. It has been found.

【0006】これに対し、咀嚼しやすいものとするため
に単に被覆される内核錠の硬度を低いものとすると、打
錠自体が困難になったり、打錠を含む錠剤の製造時、及
びその後の包装等の工程、輸送の過程等における錠剤の
破損が多くなることが考えられる。
[0006] On the other hand, if the hardness of the core tablet that is simply coated is made low in order to make it easy to chew, tableting itself becomes difficult, and it becomes difficult during tablet production including tableting and thereafter. It is conceivable that tablet damage during the packaging process, transportation process, and the like will increase.

【0007】従って、糖衣等の被覆を施した場合にも十
分にチュアブル錠として咀嚼可能なものであり、かつ上
記のような製造、流通過程における問題を生じない被覆
した咀嚼可能な錠剤を提供するための要件を設定できれ
ば、新たな剤型として多様な薬物を簡易な包装によりチ
ュアブル錠の形態で提供し得るものであり、極めて有用
であると考えられる。
Accordingly, there is provided a coated chewable tablet which can be sufficiently chewed as a chewable tablet even when coated with a sugar coating or the like and which does not cause the above-mentioned problems in the production and distribution processes. If necessary requirements can be set, various drugs as new dosage forms can be provided in the form of chewable tablets by simple packaging, and are considered to be extremely useful.

【0008】尚、従来の糖衣錠のような被覆を有する錠
剤は嚥下して服用されるものであり、咀嚼して服用する
ことを前提としていないため、硬度はかなり高く、咀嚼
できないものであった。
[0008] Tablets having a coating, such as conventional sugar-coated tablets, are swallowed and taken, and are not premised on being chewed. Therefore, they have a considerably high hardness and cannot be chewed.

【0009】[0009]

【発明が解決すべき課題】従って本発明の目的は、チュ
アブル錠として咀嚼可能であり、かつ製造、包装、流通
等の過程で破損等の問題を生じない、被覆された錠剤組
成物を提供することである。
Accordingly, an object of the present invention is to provide a coated tablet composition which can be chewable as a chewable tablet and which does not cause a problem such as breakage in the course of production, packaging, distribution and the like. That is.

【0010】[0010]

【課題を解決するための手段】本発明者らは、上記目的
を達成するために鋭意研究した結果、被覆された錠剤の
内核錠の硬度を、内核錠の錠径により規定される一定の
範囲に選択すれば、上記目的を達成できる、被覆された
咀嚼可能な錠剤を提供できることを見出した。
Means for Solving the Problems The inventors of the present invention have conducted intensive studies to achieve the above object, and as a result, the hardness of the cored tablet of the coated tablet has been set within a certain range defined by the tablet diameter of the cored tablet. It has been found that a coated chewable tablet which can achieve the above object can be provided by selecting the following.

【0011】従って本発明は、内核錠とそれを被覆する
被覆層とからなり、内核錠の硬度(N、1N=0.10
2Kg)が錠径(mm)の4倍〜8倍であることを特徴と
する咀嚼可能な被覆錠剤を提供するものである。
Accordingly, the present invention comprises a core tablet and a coating layer covering the core tablet, and the hardness of the core tablet (N, 1N = 0.10)
(2 kg) is 4 to 8 times the tablet diameter (mm).

【0012】上記本発明の被覆錠剤の好ましい態様にお
いては、被覆層が糖衣であり、被覆錠剤が糖衣錠である
ことを特徴とする。
In a preferred embodiment of the coated tablet of the present invention, the coating layer is sugar-coated and the coated tablet is sugar-coated.

【0013】上記本発明の被覆錠剤の好ましい態様にお
いては、内核錠が、酸化されやすい薬物及び変色する薬
物から選ばれる少なくとも1種の薬物を含有することを
特徴とする。
[0013] In a preferred embodiment of the coated tablet of the present invention, the core tablet contains at least one drug selected from drugs that are easily oxidized and drugs that change color.

【0014】[0014]

【発明の実施の形態】以下、本発明の実施の形態につい
て詳細に説明する。
Embodiments of the present invention will be described below in detail.

【0015】本発明の咀嚼可能な被覆錠剤(以下、単に
「本発明の錠剤」という場合がある)は、内核錠とそれ
を被覆する被覆層からなり、内核錠の硬度(N)が錠径
(mm)の4倍〜8倍であることを特徴とする。
[0015] The chewable coated tablet of the present invention (hereinafter sometimes simply referred to as "tablet of the present invention") comprises an inner core tablet and a coating layer covering the inner core tablet.
(mm) 4 to 8 times.

【0016】本発明の錠剤の形態は特に限定されない
が、通常は従来のチュアブル錠と同様の円板形とするこ
とができる。しかし、本発明の錠剤の平面形状は円形に
限定されるものではなく、楕円、四角形等の多角形等で
あってもよい。
Although the form of the tablet of the present invention is not particularly limited, it can be usually formed in the same disc shape as a conventional chewable tablet. However, the planar shape of the tablet of the present invention is not limited to a circle, but may be an ellipse, a polygon such as a square, or the like.

【0017】本発明の錠剤は内核錠に比較的薄い被覆層
を設けたものであるので、内核錠の形態により本発明の
錠剤の形態が概略決まる。この内核錠は例えば、上面及
び下面が平面で上面及び下面と側面との角が面取りされ
ていないいわゆるふちどりなしの形態、曲率を有する面
に面取りされた隅丸平面、平面で面取りされた隅角平面
等の形状、上面及び下面が曲率を有するいわゆる2段R
面、糖衣面等の形態とすることができる。2段R面、糖
衣面等が特に好ましい。また、内核錠の上面及び下面が
曲率を有しないものであっても後述するように糖衣等の
被覆層を設けることにより、本発明の錠剤の形態を上面
及び下面が曲率を有する2段R面や糖衣面の形態とする
ことができる。
Since the tablet of the present invention is provided with a relatively thin coating layer on the core tablet, the form of the tablet of the present invention is roughly determined by the form of the core tablet. This core tablet is, for example, a so-called no-edge form in which the upper and lower surfaces are flat and the corners of the upper and lower surfaces and the side surfaces are not chamfered, a rounded flat surface chamfered to a surface having a curvature, a corner angle chamfered to a flat surface A so-called two-stage R having a shape such as a flat surface and upper and lower surfaces having curvature
Surface, sugar-coated surface and the like. Particularly preferred are a two-step R surface, a sugar-coated surface and the like. Even if the upper and lower surfaces of the core tablet do not have a curvature, by providing a coating layer such as sugar coating as described later, the tablet of the present invention can be formed into a two-step R surface having upper and lower surfaces having a curvature. Or a sugar-coated surface.

【0018】本発明の錠剤の内核錠は、通常の錠剤と同
様の方法で製造することができる。すなわち、活性成分
を公知の添加剤に加えて均等に混和し、それをそのまま
圧縮成形するか(直接粉末圧縮法、直打法)、それを顆
粒に造粒し、それをそのままあるいは添加剤を加えて混
和して圧縮成形して(湿式及び乾式顆粒圧縮法、間接圧
縮法)製造できる。このような内核錠の製造は、通常の
医薬品の製造に使用されているロータリー打錠機のよう
な市販の打錠機を用いて行うことがきる。
The core tablet of the tablet of the present invention can be produced by the same method as for a normal tablet. That is, the active ingredient is added to a known additive, mixed evenly, and then compression-molded as it is (direct powder compression method, direct compression method), or granulated into granules, which can be used as it is or as an additive. In addition, it can be mixed and compression-molded (wet and dry granulation, indirect compression) to produce. The production of such a core tablet can be carried out using a commercially available tableting machine such as a rotary tableting machine used for the production of ordinary pharmaceuticals.

【0019】添加剤としては、賦形剤、結合剤、崩壊
剤、分散剤、溶解補助剤、着色剤、香料、甘味剤、高甘
味剤等が挙げられ、これらの1種以上組み合わせて使用
することができる。
The additives include excipients, binders, disintegrants, dispersants, solubilizers, coloring agents, flavors, sweeteners, sweeteners, etc., and are used in combination of at least one of them. be able to.

【0020】本発明の錠剤はチュアブル錠であることか
ら、その内核錠に用いられる賦形剤としては糖類や糖ア
ルコール類が好ましい。そのような糖類や糖アルコール
類の例としては、例えば、グルコース、フルクトース、
ガラクトース、ソルビトール、マンニトール、シュクロ
ース、マルトース、ラクトース、イソマルトース、パラ
チノース、マルツロース、ラクツロース、マルチトー
ル、ラクチトール、パラチニット、キシリトール、エリ
スリトール、トレハロース等が挙げられる。
Since the tablet of the present invention is a chewable tablet, the excipient used for the core tablet is preferably a saccharide or a sugar alcohol. Examples of such sugars and sugar alcohols include, for example, glucose, fructose,
Examples include galactose, sorbitol, mannitol, sucrose, maltose, lactose, isomaltose, palatinose, maltulose, lactulose, maltitol, lactitol, palatinit, xylitol, erythritol, trehalose and the like.

【0021】活性成分は特に限定されないが、本発明の
趣旨から酸化されやすい薬物等の成分、あるいは変色し
やすい成分であることが好ましい。酸化されやすい成分
の例としてはアスコルビン酸(ビタミンC)、ビタミン
D、ビタミンA、ビタミンB12、メキタジン、ブロム
ヘキシン、ラニチジン等が挙げられる。変色しやすい成
分の例としては、アスコルビン酸(ビタミンC)、ビタ
ミンB2等が挙げられる。活性成分は医薬活性成分に限
定されず、生理活性物質のようなその他の活性成分でも
よい。苦味やにおいのある活性成分については高分子や
糖類で予め被覆してから添加することが好ましい。
The active ingredient is not particularly limited, but is preferably a component such as a drug which is easily oxidized or a component which is easily discolored for the purpose of the present invention. Examples of components that are easily oxidized include ascorbic acid (vitamin C), vitamin D, vitamin A, vitamin B12, mequitazine, bromhexine, ranitidine and the like. Examples of components that are easily discolored include ascorbic acid (vitamin C) and vitamin B2. The active ingredient is not limited to a pharmaceutically active ingredient, but may be another active ingredient such as a physiologically active substance. It is preferable to add a bitter or odorous active ingredient after coating it with a polymer or a saccharide in advance.

【0022】本発明の錠剤の内核錠の大きさは特に限定
されないが、一般には直径(平面形状が円形でない場合
は最大径)が5〜14mm、好ましくは8〜12mm程
度である。厚さも特に限定されないが、錠径を1とした
ときに好ましくは0.3以上であり、特に好ましくは
0.5〜0.75程度である。
Although the size of the core tablet of the tablet of the present invention is not particularly limited, it is generally about 5 to 14 mm, preferably about 8 to 12 mm in diameter (the maximum diameter when the planar shape is not circular). Although the thickness is not particularly limited, it is preferably 0.3 or more when the tablet diameter is 1, and particularly preferably about 0.5 to 0.75.

【0023】上記の本発明の内核錠は、硬度(N)が錠径
(mm、上記の内核錠の平面形状直径)の4倍〜8倍とな
るように製造される。ここで内核錠の硬度は通常の錠剤
の硬度試験に使用される方法により測定される値を意味
するものであり、内核錠に圧力を加え(上面及び下面に
平行な方向)、内核錠が崩壊する際の圧力(N)で表さ
れる。この硬度の値をmmで表される錠径の4倍〜8倍
となるように打錠する。例えば、直径10mmの内核錠
の場合、硬度が40〜80Nとなるように製造する。
The hardness (N) of the core tablet of the present invention is the tablet diameter.
(mm, the planar shape diameter of the above-mentioned core tablet) is manufactured to be 4 to 8 times. Here, the hardness of the core tablet means a value measured by a method used in a normal tablet hardness test. Pressure is applied to the core tablet (in a direction parallel to the upper surface and the lower surface), and the core tablet disintegrates. Pressure (N). Tableting is performed so that the hardness value becomes 4 to 8 times the tablet diameter expressed in mm. For example, in the case of a core tablet having a diameter of 10 mm, the core tablet is manufactured to have a hardness of 40 to 80N.

【0024】このように、内核錠の硬度を錠径により規
定するのは、錠径が大きくなるほど同じ硬度では破損等
が起こりやすくなるのでより高い硬度が必要となるこ
と、錠径が大きくなればある程度硬度が高くなっても噛
み砕きやすさは損なわれないという事実に基づくもので
ある。このような所望の硬度は、打錠時の圧縮圧力、内
核錠の成分等を調整することにより容易に得ることがで
きる。このような範囲よりも硬度が低いと、製造、包
装、流通の過程等において錠剤の破損等が起こりやすく
なり、またこのような範囲よりも硬度が高いと硬度が高
すぎ、錠剤が噛み砕きにくくなる。
As described above, the hardness of the core tablet is defined by the tablet diameter. The larger the tablet diameter, the more likely it is that the same hardness will cause breakage or the like. Therefore, a higher hardness is required. This is based on the fact that even if the hardness is increased to some extent, the friability is not impaired. Such a desired hardness can be easily obtained by adjusting the compression pressure at the time of tableting, the components of the core tablet, and the like. If the hardness is lower than such a range, the tablet is likely to be damaged in the course of production, packaging, distribution, and the like, and if the hardness is higher than such a range, the hardness is too high, and the tablet becomes difficult to chew. .

【0025】尚、チュアブル錠の噛み砕きやすさは錠剤
の形状、厚さ等にも影響され得るが、上記のような内核
錠の形状、厚さにおいては、上記のように内核錠の硬度
を錠径により規定される範囲にすることにより噛み砕き
やすさが確保される。
The chewability of a chewable tablet can be affected by the shape and thickness of the tablet. However, in the shape and thickness of the core tablet as described above, the hardness of the core tablet is determined as described above. By setting the diameter in the range defined by the diameter, chewing easiness is ensured.

【0026】被覆層は上記の通り、活性成分を酸素、水
分等から遮断する目的で設けられ、例えば、糖衣、フィ
ルム、膠衣等が挙げられ、通常の錠剤コーティング装置
及び方法を用いて形成することができる。本発明の錠剤
は口腔内で咀嚼されるチュアブル錠であることから、被
覆層は糖衣であることが好ましい。
As described above, the coating layer is provided for the purpose of shielding the active ingredient from oxygen, moisture and the like, and includes, for example, sugar coating, film, glue and the like, and is formed using a usual tablet coating apparatus and method. be able to. Since the tablet of the present invention is a chewable tablet that can be chewed in the oral cavity, the coating layer is preferably sugar-coated.

【0027】これらの被覆層の成分としては、ゼラチ
ン、プルラン、アラビアゴム、セラック、ヒドロキシプ
ロピルメチルセルロース、ショ糖、炭酸カルシウム、タ
ルク、着色剤、ポリシング剤等が挙げられ、内核錠に含
有される成分のために求められる酸素、水分等の遮断性
能に基づいて選択することができる。
The components of these coating layers include gelatin, pullulan, gum arabic, shellac, hydroxypropylmethylcellulose, sucrose, calcium carbonate, talc, coloring agents, polishing agents and the like. Can be selected on the basis of the barrier performance of oxygen, moisture and the like required for the above.

【0028】被覆層の厚さは特に限定されないが、通常
は内核錠の重量を1としたときに被覆層の重量が0.1
〜1.5となるような量あるいは厚さとする。
Although the thickness of the coating layer is not particularly limited, the weight of the coating layer is usually 0.1 when the weight of the core tablet is 1.
The amount or the thickness is set to 1.5.

【0029】[0029]

【実施例】以下に、本発明を実施例及び比較例により具
体的に説明するが、本発明はこれらに限定されるもので
はない。
The present invention will be described below in more detail with reference to examples and comparative examples, but the present invention is not limited to these examples.

【0030】実施例1 直打用乳糖130mg、コーンスターチ55mg、低分
子量ヒドロキシプロピルセルロース17.5mg、低置
換度ヒドロキシプロピルセルロース(LH21)11m
g、軽質無水珪酸2.4mg、結晶セルロース18m
g、及びステアリン酸マグネシウム1.1mgを均質に
混合し、ロータリー打錠機(菊水製作所製、コレクト1
2HU)を用いて8mm糖衣面の杵で内核錠を打錠圧
0.5トンで打錠し、1錠235mgの内核錠を得た
(錠径8mm、錠厚5.20mm)。この内核錠の硬度
は32.3Nであった。
Example 1 Lactose for direct injection 130 mg, corn starch 55 mg, low molecular weight hydroxypropylcellulose 17.5 mg, low substituted hydroxypropylcellulose (LH21) 11 m
g, light silicic anhydride 2.4 mg, crystalline cellulose 18 m
g, and 1.1 mg of magnesium stearate were homogeneously mixed, and the mixture was mixed with a rotary tableting machine (Collect 1 manufactured by Kikusui Seisakusho).
Using 2HU), an inner core tablet was tableted with a punch having an 8 mm sugar-coated surface at a tableting pressure of 0.5 ton to obtain 235 mg of a core tablet (tablet diameter: 8 mm, tablet thickness: 5.20 mm). The hardness of the core tablet was 32.3N.

【0031】この錠剤3kgを通気性コーテング装置
(ドリアコーター:DRC−500、パウレック社製)
を用いてヒドロキシプロピルメチルセルロース50%及
びショ糖50%からなる被膜皮膜で1錠あたり20mg
となるようにスプレーコーティングした。その後、プル
ラン及びショ糖を主体とするシロップを用いて常法によ
り糖衣コーティングし、1錠405mgの糖衣錠を得
た。
3 kg of the tablet is coated with a breathable coating device (Doria Coater: DRC-500, manufactured by Powrex).
20mg per tablet with a film consisting of 50% hydroxypropylmethylcellulose and 50% sucrose
Was spray-coated so that Thereafter, sugar coating was carried out by a conventional method using a syrup mainly composed of pullulan and sucrose, to obtain 405 mg of a sugar-coated tablet.

【0032】実施例2 実施例1と同様の成分を使用し、同様の方法により内核
錠を製造したが、打錠圧を0.75トンとした。得られ
た内核錠の硬度は60.8N、錠径は8mm、錠厚は
5.01mmであった。この内核錠を実施例1と同様に
してコーティングし、糖衣錠を得た。
Example 2 Using the same ingredients as in Example 1, a core tablet was produced in the same manner, but the tableting pressure was 0.75 tons. The hardness of the obtained core tablet was 60.8 N, the tablet diameter was 8 mm, and the tablet thickness was 5.01 mm. This core tablet was coated in the same manner as in Example 1 to obtain a sugar-coated tablet.

【0033】比較例 実施例1と同様の成分を使用し、同様の方法により内核
錠を製造したが、打錠圧を1.0トンとした。得られた
内核錠の硬度は87.2N、錠径は8mm、錠厚は4.
91mmであった。この内核錠を実施例1と同様にして
コーティングし、糖衣錠を得た。
Comparative Example An inner core tablet was produced in the same manner as in Example 1 by using the same components, but the tableting pressure was set at 1.0 ton. The hardness of the obtained core tablet is 87.2 N, the tablet diameter is 8 mm, and the tablet thickness is 4.
It was 91 mm. This core tablet was coated in the same manner as in Example 1 to obtain a sugar-coated tablet.

【0034】実施例及び比較例の糖衣錠を口中で噛み砕
いてみたところ、実施例の糖衣錠はいずれも噛み砕くこ
とができたが、比較例の糖衣錠は噛み砕きにくかった。
When the sugar-coated tablets of the Examples and Comparative Examples were chewed in the mouth, all of the sugar-coated tablets of the Examples could be chewed, but the sugar-coated tablets of the Comparative Example were difficult to chew.

【0035】[0035]

【発明の効果】本発明の被覆錠剤は、チュアブル錠とし
て咀嚼可能であり、かつ製造、包装、流通等の過程で破
損等の問題を生じない錠剤であり、新たな剤型として、
多様な薬物をチュアブル錠の形態で提供し得るものであ
り、極めて有用である。
The coated tablet of the present invention is a tablet that can be chewable as a chewable tablet and does not cause problems such as breakage in the course of production, packaging, distribution and the like.
A variety of drugs can be provided in the form of chewable tablets, which is extremely useful.

───────────────────────────────────────────────────── フロントページの続き (72)発明者 中川 泰緒 東京都豊島区高田3丁目24番1号 大正製 薬株式会社内 (72)発明者 山崎 孝 東京都豊島区高田3丁目24番1号 大正製 薬株式会社内 Fターム(参考) 4C076 AA37 BB01 DD27 DD41 DD67 EE31 EE33 EE38 FF26 FF27 GG14 GG16  ──────────────────────────────────────────────────続 き Continuing on the front page (72) Inventor Yasushi Nakagawa 3- 24-1, Takada, Toshima-ku, Tokyo Taisho Pharmaceutical Co., Ltd. (72) Inventor Takashi Yamazaki 3- 24-1, Takada, Toshima-ku, Tokyo F term (reference) in Taisho Yaku Co., Ltd. 4C076 AA37 BB01 DD27 DD41 DD67 EE31 EE33 EE38 FF26 FF27 GG14 GG16

Claims (3)

【特許請求の範囲】[Claims] 【請求項1】 内核錠とそれを被覆する被覆層とからな
り、内核錠の硬度(N)が錠径(mm)の4倍〜8倍である
ことを特徴とする咀嚼可能な被覆錠剤。
1. A chewable coated tablet comprising a core tablet and a coating layer covering the core tablet, wherein the hardness (N) of the core tablet is 4 to 8 times the tablet diameter (mm).
【請求項2】 被覆層が糖衣であり、糖衣錠であること
を特徴とする請求項1に記載の咀嚼可能な被覆錠剤。
2. The chewable coated tablet according to claim 1, wherein the coating layer is a sugar-coated tablet and is a sugar-coated tablet.
【請求項3】 内核錠が、酸化されやすい薬物及び変色
する薬物から選ばれる少なくとも1種の薬物を含有する
ことを特徴とする請求項1または2に記載の咀嚼可能な
被覆錠剤。
3. The chewable coated tablet according to claim 1, wherein the core tablet contains at least one drug selected from drugs that are easily oxidized and drugs that change color.
JP11109212A 1999-04-16 1999-04-16 Chewable coated tablet Pending JP2000302672A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP11109212A JP2000302672A (en) 1999-04-16 1999-04-16 Chewable coated tablet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP11109212A JP2000302672A (en) 1999-04-16 1999-04-16 Chewable coated tablet

Publications (1)

Publication Number Publication Date
JP2000302672A true JP2000302672A (en) 2000-10-31

Family

ID=14504448

Family Applications (1)

Application Number Title Priority Date Filing Date
JP11109212A Pending JP2000302672A (en) 1999-04-16 1999-04-16 Chewable coated tablet

Country Status (1)

Country Link
JP (1) JP2000302672A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538104A (en) * 2002-07-26 2005-12-15 メルク シャープ エンド ドーム リミテッド Composition comprising cholesterol absorption inhibitor, HMG-CoA reductase inhibitor and stabilizer
WO2006075502A1 (en) * 2004-12-24 2006-07-20 Kaneka Corporation Solid preparation comprising reduced coenzyme q10 and process for production of the same
WO2014157264A1 (en) * 2013-03-27 2014-10-02 Meiji Seikaファルマ株式会社 Film-coated orally disintegrating tablet
US9693962B2 (en) 2012-06-05 2017-07-04 Takeda Pharmaceutical Limited Dry-coated tablet

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005538104A (en) * 2002-07-26 2005-12-15 メルク シャープ エンド ドーム リミテッド Composition comprising cholesterol absorption inhibitor, HMG-CoA reductase inhibitor and stabilizer
US7718643B2 (en) 2002-07-26 2010-05-18 Schering Corporation Pharmaceutical formulation
WO2006075502A1 (en) * 2004-12-24 2006-07-20 Kaneka Corporation Solid preparation comprising reduced coenzyme q10 and process for production of the same
JP5021319B2 (en) * 2004-12-24 2012-09-05 株式会社カネカ Solid preparation containing reduced coenzyme Q10 and method for producing the same
US9693962B2 (en) 2012-06-05 2017-07-04 Takeda Pharmaceutical Limited Dry-coated tablet
WO2014157264A1 (en) * 2013-03-27 2014-10-02 Meiji Seikaファルマ株式会社 Film-coated orally disintegrating tablet
JPWO2014157264A1 (en) * 2013-03-27 2017-02-16 Meiji Seikaファルマ株式会社 Orally disintegrating film-coated tablets

Similar Documents

Publication Publication Date Title
JP7216055B2 (en) Pharmaceutical composition
JP5352474B2 (en) Orally disintegrating tablet and method for producing the same
US9358207B2 (en) Flashmelt oral dosage formulation
US8486450B2 (en) Method of producing solid preparation disintegrating in the oral cavity
Prateek et al. Fast dissolving tablets: a new venture in drug delivery
RU2203046C2 (en) Method for flubiprophen tablet making
CA3069563A1 (en) Preparation comprising vonoprazan
EP1441698B1 (en) Flashmelt oral dosage formulation
JP3119801B2 (en) Method for stabilizing a vitamin-containing composition
JP5337430B2 (en) Orally disintegrating tablets
EP2848242A1 (en) Orally disintegrating formulations of Linagliptin
EP2370062B1 (en) Formulations for systemic buccal delivery comprising s- adenosylmethionine, their preparation and use
JP5572321B2 (en) Orally disintegrating tablets containing coated fine particles
JP2000302672A (en) Chewable coated tablet
US20020127184A1 (en) Effervescent tablet compositions
JP2009196940A (en) Tablet quickly disintegrating in oral cavity and its production method
JP2004026786A (en) Vitamin preparation
JP6963281B2 (en) Ibuprofen-containing tablets
JP2023173283A (en) Granule and manufacturing method thereof, and tablet
OKOLIE FORMULATION AND OPTIMIZATION OF MODIFIED RELEASE IBUPROFEN ORAL DISINTEGRATING TABLET BY DIRECT COMPRESSION
JPH10316556A (en) Stable solid agent containing oral cavity disintegration type volatile medicine and its production
Saharan Modifications in Conventional Tablet Compaction Technologies for Developing Fast Dissolving/Disintegrating Tablets
KR20190120096A (en) Oral tablet formulation of lenalidomide with improved disintegration
Diliprao Formulation and Evaluation of Orodispersible Tablets of Amlodipine Besilate
Eemana Formulation and Evaluation of Deferasirox Dispersible Tablets